FMP
iShares Genomics Immunology and Healthcare ETF
IDNA
AMEX
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
22.83 USD
0.04 (0.175%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
AMEX
Description
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
CIK
0001100663
ISIN
US46435U1925
CUSIP
46435U192
Address
N/A
Phone
NA
Country
US
Employee
N/A
IPO Date
Jun 14, 2019
Sector Weightings
We are unable to load the chart at this time.
Country Weightings
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
IDNA Financial Summary
ISIN
US46435U1925
Exchange
AMEX
Beta
1.15
Market Cap
140.71M
52-Week
21.53-25.8
Volume Avg.
33.77k
Price
22.83
Country
US
Management Assets
-
Total Holdings
-
NAV
-
NAV Currency
-
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IDNA News
It looks like there's no news available.
